Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
Related reading
Merck’s record cancer drug sales power earnings growth
Quarterly proceeds from Keytruda top $8bn for first time
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Merck splits operations to separate oncology from non-cancer drugs
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda
Big pharma’s scramble over the patent cliff will be costly
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
Pfizer shows hardball mettle needed to win in 2025 M&A
Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk
Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn
US company is attempting to acquire the maker of a new treatment for pancreatic cancer